Actively Recruiting
Nutritional Sources of Salicylates and Placental Angiogenesis Disorders in Preeclampsia
Led by Poznan University of Life Sciences · Updated on 2026-04-01
500
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Preeclampsia (PE) is a serious pregnancy complication causing significant maternal and fetal health issues, including many deaths worldwide. It involves problems with placental function related to blood vessel growth (angiogenesis). Researchers are studying whether natural food sources of salicylates affect placental angiogenesis and the development of PE, comparing these effects to those of low-dose aspirin, which is known to reduce PE risk. This observational study aims to understand the relationship between maternal dietary salicylate intake and placental health in about 500 pregnant women aged 18 to 45. The study will collect detailed daily dietary information using questionnaires and interviews to measure salicylic acid and total salicylate intake. Blood samples taken at delivery will be tested for salicylates, inflammatory markers, and angiogenesis biomarkers such as VEGF, PLGF, and sFLT1. Placental tissue will also be analyzed for these biomarkers and vascularization. Additionally, participants will collect 24-hour urine samples to measure salicylates. Participants will provide dietary and medical information throughout pregnancy, with blood and placental samples collected at delivery. Researchers will monitor biomarkers related to inflammation and placental blood vessel growth to assess how salicylates affect PE risk. The study will last about three years, helping to develop future dietary recommendations for PE prevention and treatment, potentially reducing complications and healthcare costs.
CONDITIONS
Brief Title
Dietary Salicylates and Preeclampsia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 45 years
- Healthy women or women diagnosed with preeclampsia
- Pregnancy with a single fetus (singleton pregnancy)
- Ability to provide informed consent
You will not qualify if you...
- Pregnancies with detectable fetal defects, chromosomal abnormalities, or genetic syndromes
- Presence of infections
- History of chronic hypertension, metabolic disorders before or during pregnancy
- High-risk conditions such as heart disease, diabetes, or kidney disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Throughout pregnancy until delivery
Participants provide information on daily food intake and undergo dietary intake interviews to assess natural salicylate consumption.
Dietary assessments occur multiple times during pregnancy
Duration - At delivery
Blood and urine samples are collected at the time of delivery to measure salicylates, inflammatory biomarkers, and angiogenesis biomarkers. Placentas are collected after delivery for further biomarker analysis and vascularization evaluation.
1 visit at delivery (in-person) for blood, urine, and placenta collection
Duration - Up to 3 years
Participants' dietary intake and biomarker levels are observed and evaluated over a period of up to 3 years.
Trial Site Locations
Total: 1 location
1
Poznan University of Life Sciences
Poznan, Poland, 60-624
Actively Recruiting
Research Team
J
Joanna Suliburska, Professor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here